Investors
Investors
Creating value for stakeholders
We are an established, commercial-stage diagnostics company.
We are an established, commercial-stage diagnostics company with over 30 years’ experience of manufacturing and supplying the conventional reagent products used for blood grouping within the $3.4 billion global transfusion diagnostics market.


Our proprietary technology platform, MosaiQ, is continually been developed and enhanced to better address the comprehensive needs of this large and established market. We believe MosaiQ has the potential to be a transformative technology that significantly reduces the cost of blood grouping in both donor and patient-testing environments.

Investors

4:00 PM EDT • Feb 24, 2020
QTNT
6.84USD
+1.79%
3 Months
6 Months
12 Months
USD

Events & presentations

Quotient Limited Fiscal Third Quarter 2020 Financial Results
J.P. Morgan Healthcare Conference

Press releases

Quotient Limited Reports Concordance Data from Extended Serological Disease Screening Benchmark Study
Quotient Limited Announces CE Mark Approval for Initial Serological Disease Screening Microarray
Quotient Limited Provides an Update on Recent MosaiQ Milestone Achievements together with Third Quarter Fiscal 2020 Results
Financials & filings

Get up-to-date information about our Company’s financials.

Corporate governance

Retrieve corporate policy documents, committee charters, and more. 

Stock information

Follow our latest stock quote and historical information.

Our reagents by Quotient
Alba by Quotient. Experience. Expertise. Value.
These are just some of the qualities that set us apart from the competition. You can have peace of mind using our products, which have been time-tested for more than 30 years.